Sažetak
Background: Accurate and efficient chemical analyzers play a critical role in modern healthcare, particularly in community medicine where early diagnosis and intervention can significantly improve patient outcomes. This study evaluated the diagnostic performance of the novel portable ENNOLIFE HCA-TC-200 analyzer compared to the established Beckman UniCel DxC 880i analyzer, emphasizing its application for point-of-care testing in community settings.
Methods: A total of 600 healthy subjects were recruited from Shuang Ho Hospital, Taiwan. The diagnostic accuracy of ENNOLIFE HCA-TC-200 was validated using clinical chemistry assays, specifically assessing hepatic, renal, and urinary biomarkers. The analyzers were compared based on linearity, inter-method agreement, accuracy, and precision.
Results: The ENNOLIFE HCA-TC-200 analyzer demonstrated diagnostic accuracy and precision comparable to the Beckman UniCel DxC 880i. High linear correlations (R > 0.97) were found for most hepatic, renal, and urinary markers, with minor deviations observed for albumin (R = 0.92) and urine creatinine (R = 0.80), which remained within clinically acceptable diagnostic ranges. Accuracy assessments showed >97% inter-method agreement across all analytes after excluding extreme outliers, with 100% agreement for hepatic and renal markers.
Conclusions: Chronic liver and kidney diseases remain significant public health challenges, especially within community healthcare contexts. The portable ENNOLIFE HCA-TC-200 analyzer effectively addresses these challenges by facilitating rapid, accurate point-of-care diagnostics in community-based settings. This device supports timely disease detection, enhances preventive medicine practices, and promotes personalized healthcare, ultimately contributing to improved community health outcomes.
Ključne reči
Array
Array
Array
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.